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Hepatocellular carcinoma (HCC) is the ﬁfth most common malignant tumor worldwide, and is the third
most common cause of cancer related death. Constitutive activation of NF-jB is the underlying mecha-
nism behind tumorigenesis and this protein regulates the expression of genes involved in proliferation,
survival, drug resistance, angiogenesis and metastasis. The design of inhibitors which suppress NF-jB
activation is therefore of great therapeutic importance in the treatment of HCC. In this study, we inves-
tigated the effect of newly synthesized coumarin derivatives against HCC cells, and identiﬁed (7-Carbeth-
oxyamino-2-oxo-2H-chromen-4-yl)methylpyrrolidine-1 carbodithioate (CPP) as lead compound. Further,
we evaluated the effect of CPP on the DNA binding ability of NF-jB, CXCL12-induced cell migration and
invasion, and the regulated gene products in HCC cells. We found that CPP induced cytotoxicity in three
HCC cells in a time and dose dependent manner, and suppressed the DNA binding ability of NF-jB. CPP
signiﬁcantly decreased the CXCL12-induced cell migration and invasion. More evidently, CPP inhibits the
expression of NF-jB targeted genes such as cyclin D1, Bcl-2, survivin, MMP12 and C-Myc. Furthermore,
the molecular docking analysis suggested that CPP interacts with the p50 binding domain of the p65 sub-
unit, scoring best among the 26 docked coumarin derivatives of this study. Thus, we are reporting CPP as
a potent inhibitor of the pro-inﬂammatory pathway in Hepatocellular carcinoma.
 2014 Elsevier Ltd. All rights reserved.Hepatocellular carcinoma (HCC) is the most common form of
liver cancer, and is the third most common cause of cancer related
mortality.1 Obesity, hepatitis B or hepatitis C virus infection, con-
sumption of aﬂatoxin B1, and alcoholic hepatitis are the major risk
factors of HCC.2 The majority of patients with HCC are diagnosed at
a late stage of the disease, with therapy limited to only liver trans-
plantation and surgical liver sectioning. Early detection of HCCmay
contribute to the strengthening of prognosis.3,4 Nuclear factorkappa B (NF-jB) is an inducible transcription factor present ubiqui-
tously in the cytoplasm of almost all mammalian cells, and was
identiﬁed by Baltimore and colleagues in 1986.5 In an unstimulated
cell, NF-jB is associated with IjB (inhibitory jB), and resides in the
cytoplasm.6 Different ligands acting upon the receptor result in a
cascade of upstream kinases, ﬁnally leading to phosphorylation
and ubiquitylation of IjB, which is targeted for degradation. NF-
jB translocates into nucleus and regulates transcription of the
genes involved in inﬂammation.7 NF-jB is referred to as a dou-
ble-edged sword by researchers because of its critical role in proper
functioning of the immune system, and the possibility that onco-
genesis may arise from the slightest change in regulation.8 Several
anti-apoptotic, angiogenic, inﬂammatory, metastasis-related, and
Figure 1. Synthesis of coumarin-based small molecules libraries.
Figure 2. (A) HepG2 cells (5  103/mL) were plated in triplicate, treated with
indicated concentrations of CPP, and then subjected to MTT assay after 24, 48 and
72 h to analyze proliferation of cells. Standard deviations between the triplicates
are indicated. ⁄Indicates p value <0.05. (B) CPP potentiates PARP cleavage. HepG2
cells (2  106/mL) were treated with CPP for time intervals, after which whole-cell
extracts were prepared and 30 lg protein of those extracts were resolved on 10%
SDS–PAGE, membrane sliced according to molecular weight and probed against
PARP antibodies. The same blots used to detect b-actin to verify equal protein
loading.
Figure 3. (A) CPP suppresses NF-jB DNA binding ability in HepG2 cells. HepG2 cells
were treated with 50 lM CPP for indicated time points; nuclear extracts were
prepared, and 5 lg of the nuclear extract protein was used for ELISA-based DNA
binding assay. The results shown are representative of two independent experi-
ments ⁄P <0.05. (B) CPP suppresses NF-jB regulated gene products involved in
proliferation, survival and angiogenesis. HepG2 cells (2  106/mL) were treated
with 50 lM CPP for indicated time intervals, after which whole-cell extracts were
prepared and 30 lg proteins of those extracts were resolved on 10% SDS–PAGE,
membrane sliced according to molecular weight and probed against cyclin D1, Bcl-
2, survivin and C-Myc antibodies. The same blots were stripped and reprobed with
b-actin antibody to verify equal protein loading. The results of cyclin D1, Bcl-2,
survivin and C-Myc shown are representative of two independent experiments. (C)
CPP induces MMP12 cleavage. HepG2 cells (2  106/mL) were treated with CPP for
indicated concentrations, after which whole-cell extracts were prepared and 30 lg
proteins of those extracts were resolved on 10% SDS–PAGE, membrane sliced
according to molecular weight and probed against MMP12 antibodies. The same
blots used to detect b-actin to verify equal protein loading.
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COX2, are regulated by NF-jB signaling.8,9
Coumarins were originally isolated in early 1820 from tonka
beans, and were later used for various domestic purposes.10 Since
Figure 4. CPP suppresses migration in HCC cells. An IBIDI culture insert (IBIDI GmbH) consists of two reservoirs separated by a 500 lm thick wall created by a culture insert
in a 35 mm petri dish. For migration assay, an equal number of HepG2 cell (70 lL; 5  105 cells/mL) were added into the two reservoirs of the same insert and incubated at
37 C. After 12 h, the insert was gently removed creating a gap of 500 lm. The cells were treated with CPP (50 lM) for 8 h before being exposed to 100 ng/mL CXCL12 for
24 h. Width of wound was measured at time zero and 24 h of incubation in the absence or presence of CXCL12. The representative photographs showed the same area at time
zero and after 24 h of incubation and columns represent mean distance of migrated cells in the presence or absence of CPP and CXCL12.
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number of coumarin based natural compounds with different phar-
macological properties. Fraxetin, esculetin, and daphnetin are some
of the coumarin related natural compounds with very good
inhibitory activity against cyclooxygenase and lipoxygenase.11
Researchers have exploited the anti-tumor, appetite-suppressor,
anti-inﬂammatory and antioxidant activities of many natural and
synthetic coumarin based compounds both in vitro and in vivo.12
As part of our continued research into identiﬁcation of new inhibi-
tors against various signaling cascades in cancer and inﬂammation,
herein, we investigated whether coumarins may exert their anti-
cancer effect by disruption of NF-jB signaling.13–19 We synthesized
a library of coumarin derivatives, and evaluated their effect on
Hepatocellular carcinoma cells. We found (7-Carbethoxyamino-
2-oxo-2H-chromen-4-yl)methylpyrrolidine-1 carbodithioate (CPP)
to be a potent cytotoxic molecule, causing signiﬁcant reduction in
NF-jB targeted gene products, increasing apoptosis, and suppress-
ing the DNA binding ability of NF-jB.
The synthetic route for coumarin-based small molecule libraries
is outlined in Figure 1. 4-Bromoethylacetoacetate is obtained from
the bromination of ethyl-acetoacetate, and subsequently treated
with various substituted phenols under Pechmann cyclization
conditions using concentrated sulfuric acid as the dehydratingagent,20 which results in the formation of substituted-4-bro-
momethylcoumarins 1(a–m). A one pot reaction of carbon disul-
ﬁde and dimethylamine/pyrrolidine in ethanol was prepared for
compounds 1(a–m), stirring at room temperature for 24 h, which
resulted in the formation of coumarinyldithiocarbamates (Fig. 1).
Organic materials were extracted with dichloromethane, before
being separated and dried over anhydrous Na2SO4. The solvent
was removed under reduced pressure to obtain the desired prod-
ucts, and the crude product was further puriﬁed by ﬂash column
chromatography. In some cases, it was necessary to obtain
crystallized structures from the mixture of ethanol and chloroform
solvents. The structures of all the target compounds were charac-
terized by elemental analysis, GCMS, IR, 1H NMR, and 13C NMR
spectrometry.
We investigated cytotoxic effect of a newly synthesized series
of compounds on HepG2 cells using an MTT assay as described pre-
viously (Supplementary Table 3).21,22 CPP was found to be most
effective compound among the tested compounds, and MTT assay
was used to further investigate whether CPP can inhibit the prolif-
eration of HepG2, PLC/PRF5, and Huh7. Our results showed that
CPP inhibits the proliferation of all the three cell lines (data not
shown for PLC/PRF5 and Huh7) in both a dose and time dependent
manner (Fig. 2A). However CPP did not show high cytotoxic effect
Figure 5. CPP suppresses invasion in HCC cells. A, HepG2 (1  105 cells) were
seeded in the top-chamber of the BD Matrigel invasion chamber. After pre-
incubation with or without 50 lM CPP for 8 h, transwell chambers were then
placed into the wells of a 24-well plate into which we added either the basal
medium only or basal medium containing 100 ng/mL CXCL12 in a predetermined
arrangement. After incubation, for 24 h cell invasion was analyzed and columns
represent mean percentage of invaded cells.
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have cytotoxic effect on normal cells.
We also investigated whether suppression of constitutively
active NF-jB in HepG2 cells by CPP leads to apoptosis. CPP induced
time-dependent cleavage of a 116 kDa Poly ADP-ribose polymerase
(PARP) protein into an 85 kDa fragment (Fig. 2B). These results
clearly suggest that CPP induces substantial apoptosis in HepG2
cells.
NF-jB is a transcription factor that plays an important role in
cell proliferation and survival. Therefore, we investigated whether
CPP can modulate the DNA binding activity of NF-jB in HCC cells.
Analysis of nuclear extracts prepared from HepG2 cells, using an
ELISA based TransAM NF-jB assay kit, showed that CPP inhibited
the NF-jB-DNA binding activities in a time dependent manner
(Fig. 3A). These results suggest that CPP can suppress the DNA
binding ability of NF-jB.
NF-jB activation has been shown to regulate the expression of
various gene products involved in cell survival, proliferation, angi-
ogenesis and chemoresistance.5,23,24 We found that expression of
the cell cycle regulator cyclin D1, and the antiapoptotic proteins
Bcl-2, survivin, and, C-Myc, and MMP12 which are reported to be
regulated by NF-jB, were modulated by CPP treatment. Their
expression decreased across different dose and time intervals
(Fig. 3B and C).
We also determined the effect of CPP on HCC cell invasion, a key
hallmark of cancer.25,26 Using an in vitro migration assay, we found
that HepG2 cells migrated faster under the inﬂuence of CXCL12,
and this effect was abolished upon treatment with CPP (Fig. 4).
To elucidate further the effect of CPP on CXCL12-induced cell inva-
sion, we used the BD BioCoat Matrigel invasion assay system and
found that treatment with CPP suppressed CXCL12-induced inva-
sion of HepG2 cells (Fig. 5).
We simulated molecular docking of coumarins with a IjBa/NF-
jB crystal structure (PDB: 1IKN). For details of the docking routine,
please see Supplementary information. Docked coumarins were
observed at the interface of p65 (a subunit of NF-jB) and IjBa
(an inhibitory protein of NF-jB), thereby replacing the p50
sub-unit in the complex (Fig. 6). A hydrophobic cavity formed by
His-245 and Arg-246 of p65 and Tyr-248, Tyr-251, and Tyr-289 is
targeted. These regions are partially occupied by Val-251 and
Leu-269 in the native complex with p50. Lead compound CPP
scored best amongst the 26 docked coumarin compounds. In
addition to the hydrophobic interactions predicted for most
members of the series, this compound extends further into a more
polar region. Thereby, we observe hydrogen bonding between
CPP’s ester moiety and the side-chain of Tyr-251 and hydrogen
bonding to the backbone of Ser-288. The coumarin scaffold is
tightly bound via Van der Waals interactions and a hydrogen bond
to the backbone of Asp-290.
In conclusion, the over activation of NF-jB in cancer cells pro-
vides a unique target for the design of therapeutic agents. NF-jB
is reported to regulate more than 200 genes connected to cell pro-
liferation (cyclin D1 and C-Myc), survival (survivin), anti-apoptosis
(Bcl-2), inﬂammation (COX2), angiogenesis (VEGF), and metastasis
(MMPs).8,27 Of these gene products, cyclin D1 and C-Myc are cru-
cial cell cycle regulators involved in proliferation, Bcl-2 and survi-
vin are anti-apoptotic proteins, and survivin is reported to
associate with drug resistance in breast cancer.28 MMPs are a large
class of proteins with more than 20 types, and generally noted as
extracellular matrix degrading proteases. Many MMPs contribute
to the dislodging and migration of tumor cells, and have been
implicated in cancer progression. MMP1, MMP3 and MMP12 are
the major NF-jB regulated matrix metalloproteinase genes. The
role of MMP12 in cancer development is not articulate, but
researchers correlated the elevated levels of MMP12 with poor
prognosis of HCC in the past.29 Blockade of NF-jB DNA bindingcan result in suppression of its gene products. Therefore, we inves-
tigated whether the NF-jB signaling in HepG2 cells can be modu-
lated by newly synthesized coumarins. Among the new series of
coumarins, CPP proved to be a potent anti-proliferative agent
against all the three HCC cells and did not show toxicity towards
non-diseased cells. Further evaluation showed that CPP decrease
the DNA binding ability of NF-jB, indicating the possible reduction
in corresponding gene products. This reduction was apparent dur-
ing evaluation of the levels of NF-jB regulated gene products such
as cyclin D1, Bcl-2, Survivin, C-Myc, and MMP12. PARP is an inte-
gral part of cellular DNA repair machinery and a target of cas-
pase-3 and caspase-7.30 Our western blotting results clearly
suggest the cleavage of PARP from a 116 kDA protein into an
89 kDA fragment, evidencing that CPP induces apoptosis. We also
found that CPP exert anticancer effects by inhibiting migration
and invasion of HCC cells. Thus, our results strongly demonstrate
that the anti-oncogenic property of CPP in HCC is mediated
through suppression of NF-jB signaling pathway.
Figure 6. Predicted molecules interactions between CPP and the IjBa/NF-jB complex. (A) Ribbon diagram of the native IjBa/NF-jB complex. The p50 sub-unit is show in
green, p65 in cyan, and IjBa in pink. (B) Ensemble of docking solution for the 26 coumarin compounds (in stick representation, and atomic coloring with green carbons)
targeting the p50/p65 interface. (C) Close-up view of the binding mode of lead compound CPP. CPP shows hydrogen bonding (yellow dots) to the backbone of Ser-288, the
backbone of Asp-290, and the side-chain of Tyr-251.
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